Biotech finance, this week.

SEC moves to roll back shareholder proxy proposal rules

The details of the plan to rescind Rule 14a-8 come on the heels of the SEC’s push to make quarterly reporting by public companies optional.

North Immunology joins biotech reverse merger boom with Aethlon deal

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

SEC faces delays on semiannual reporting proposal amid record number of comment letters

When the Securities and Exchange Commission (SEC) in May issued a proposal that would give public companies the option to …

Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets

Electra amasses $350M in biotech’s latest big IPO

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

Statement on Proposals to Rescind Rule 14a-8, Amend Rule 14a-4, and Modernize Proxy Solicitation

SEC Chairman Paul S. Atkins

A Parkinson's biotech debut, fundraising campaign and licensing deal

Plus news about Altis Labs, Matisse Pharmaceuticals, AstraZeneca, Novo, Longeveron, Connexus Therapeutics and Avacta. A new Parkinson’s biotech: The Michael J. Fox Foundation is supporting a non-hallucinogenic…

SEC Grants Exemptive Relief from Certain Inline XBRL Filing or Submission Requirements

The Securities and Exchange Commission issued an order granting exemptive relief from certain Inline XBRL requirements adopted on Dec. 16, 2024. More specifically, the Commission is granting exemptive relief from filing…

Electra's $350M IPO will help it become a commercial biotech

Electra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay Area biotech will use the ...

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

Anaconda CFO’s IPO chops bring ‘optionality’

The AI-development company’s newly minted CFO Stewart Grierson said going public is just one path that companies can take as they evolve and grow.

8 biotech IPO prospects testing investor appetite

Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.

This week in charts: GSK’s China deals, the $300M IPO club and selling the news

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

PCAOB reorganizes, reverts Investor Advocate role to communications office

The Public Company Accounting Oversight Board (PCAOB) is eliminating its standalone Office of the Investor Advocate and moving the Investor Advocate …

FASB updates investment company fair value reporting standard

The amendments address stakeholder concerns that current GAAP guidance doesn’t consider a contractual restriction on the sale of an equity security when measuring the fair value of that security.

French biotech with Cambridge office weighs U.S. IPO after Sanofi investment

FASB proposes several incremental improvements to GAAP

In addition to language tweaks, the proposed Accounting Standards Update includes clarifications related to estimates of expected credit losses and several other topics.

SEC Proposes Rescission of Political Contribution Rule for Investment Advisers

The Securities and Exchange Commission today issued a proposal to rescind its “pay-to-play” rule that prohibits investment advisers from providing compensated investment advisory services to a government client for two…

SEC and FDA Announce MOU to Bolster Cooperation and Ensure Market Integrity

The Securities and Exchange Commission and the Food and Drug Administration today announced that they have entered into a Memorandum of Understanding (MOU) designed to assist the agencies in carrying out their…

Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs

General Catalyst details tech partnerships at Summa Health

About a year after the venture investor General Catalyst went through with its unusual plans to buy a hospital group, it's finally talking more about how it will use the experiment. ...

The biotech IPO window keeps opening

Iran war to spur inflation by 0.6 percentage point by Q1 2027: CBO study

“Re-escalation of the war in the Middle East” was the key factor behind a Federal Reserve decision to raise the main interest rate, Yardeni Research President Ed Yardeni said.

PCAOB finalizes simplified quality control amendments

QC 1000, A Firm’s System of Quality Control, will be effective Dec. 15 and could serve as the basis for the PCAOB’s future approach to inspections of public company compliance.

Risk oversight shifts into a full board priority

Increasingly complex risk profiles lead boards to expand focus beyond risk and audit committees, finds a new Ernst & Young report.

On the move: Louis Plung names first CGO

Plus, Citrin Cooperman launches transfer pricing practice; KNAV debuts enterprise GRC platform; and other firm and personnel news.

Oura files to goes public, reported $1.2B in earnings

In health tech news today, Oura reports a profit, the FDA loses another key digital health leader, and more

3 KRAS drugs to watch as the field expands

Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

What Investors Expect Before a Life Sciences IPO